CAPRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Stats
本日の出来高	290 630
平均出来高	319 185
時価総額	171.06M
EPS	$0 ( 2024-02-29 )
次の収益日	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.54
ATR14	$0.0150 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-23	Collier Earl M Jr	Buy	30 000	Common Stock
2024-04-23	Collier Earl M Jr	Sell	30 000	Stock Option (Right to Buy)
2024-04-23	Musket David B	Buy	16 156	Common Stock
2024-04-23	Musket David B	Sell	5 750	Stock Option (Right to Buy)
2024-01-02	Kelliher Mike	Buy	30 000	Stock Option (Right to Buy)

INSIDER POWER
79.00
Last 97 transactions
Buy: 2 824 525 \| Sell: 392 146

ボリューム相関

長: 0.16 (neutral)

短: 0.88 (strong)

Signal:(51.565) Same movement expected

Capricor Therapeutics Inc 相関

10 最も正の相関
QNST	0.827
LPTH	0.822
MNDY	0.811
CLMT	0.805

10 最も負の相関
LMST	-0.823
NVEI	-0.82

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Capricor Therapeutics Inc 相関 - 通貨/商品

-0.66
( moderate negative )

0.00
( neutral )

-0.71
( moderate negative )

0.66
( moderate )

0.74
( moderate )

Capricor Therapeutics Inc 財務諸表

Annual	2023
収益:	$25.18M
総利益:	$24.11M (95.75 %)
EPS:	$-0.830

FY	2023
収益:	$25.18M
総利益:	$24.11M (95.75 %)
EPS:	$-0.830

FY	2022
収益:	$2.55M
総利益:	$1.85M (72.74 %)
EPS:	$-1.180

FY	2021
収益:	$245.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.000867

Financial Reports:

No articles found.

Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.